JP2018520094A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520094A5 JP2018520094A5 JP2017559025A JP2017559025A JP2018520094A5 JP 2018520094 A5 JP2018520094 A5 JP 2018520094A5 JP 2017559025 A JP2017559025 A JP 2017559025A JP 2017559025 A JP2017559025 A JP 2017559025A JP 2018520094 A5 JP2018520094 A5 JP 2018520094A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- seq
- pharmaceutical composition
- composition according
- signaling inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021131870A JP2021191755A (ja) | 2015-05-13 | 2021-08-13 | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562161136P | 2015-05-13 | 2015-05-13 | |
| US62/161,136 | 2015-05-13 | ||
| US201562173836P | 2015-06-10 | 2015-06-10 | |
| US62/173,836 | 2015-06-10 | ||
| US201562243457P | 2015-10-19 | 2015-10-19 | |
| US62/243,457 | 2015-10-19 | ||
| PCT/US2016/031999 WO2016183280A1 (en) | 2015-05-13 | 2016-05-12 | Treatment of beta-thalassemia using actrii ligand traps |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131870A Division JP2021191755A (ja) | 2015-05-13 | 2021-08-13 | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520094A JP2018520094A (ja) | 2018-07-26 |
| JP2018520094A5 true JP2018520094A5 (cg-RX-API-DMAC7.html) | 2019-06-20 |
| JP6976859B2 JP6976859B2 (ja) | 2021-12-08 |
Family
ID=57248528
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017559025A Expired - Fee Related JP6976859B2 (ja) | 2015-05-13 | 2016-05-12 | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
| JP2021131870A Pending JP2021191755A (ja) | 2015-05-13 | 2021-08-13 | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021131870A Pending JP2021191755A (ja) | 2015-05-13 | 2021-08-13 | ＡｃｔＲＩＩリガンドトラップを用いたβ−サラセミアの治療 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20180125928A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3294320A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6976859B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102640198B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107847562A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2016261913B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2985777A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1251157A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL284686B2 (cg-RX-API-DMAC7.html) |
| JO (1) | JOP20160092B1 (cg-RX-API-DMAC7.html) |
| MY (1) | MY189601A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12017502079A1 (cg-RX-API-DMAC7.html) |
| TN (1) | TN2017000468A1 (cg-RX-API-DMAC7.html) |
| TW (2) | TWI814187B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016183280A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7612041B2 (en) | 2005-11-23 | 2009-11-03 | Acceleron Pharma Inc. | Isolated activin-binding ActRIIa polypeptide comprising the SEQ ID NO: 7 and uses for promoting bone growth |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| US8058229B2 (en) | 2008-08-14 | 2011-11-15 | Acceleron Pharma Inc. | Method of increasing red blood cell levels or treating anemia in a patient |
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| AU2013337677B2 (en) | 2012-11-02 | 2018-06-28 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| BR122023023170A2 (pt) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| MA41119A (fr) | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| CN107533040B (zh) | 2014-12-03 | 2022-03-29 | 细胞基因公司 | 激活素-actrii拮抗剂及用于治疗贫血症的用途 |
| JP2018522579A (ja) | 2015-05-20 | 2018-08-16 | セルジーン コーポレイション | アクチビンＩＩ型受容体リガンドトラップを使用するβ−サラセミアのインビトロ細胞培養法 |
| EP3370754A4 (en) | 2015-11-04 | 2019-10-23 | Acceleron Pharma Inc. | METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE |
| WO2017091706A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| US10722558B2 (en) * | 2016-07-15 | 2020-07-28 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| EA201990226A1 (ru) | 2016-07-27 | 2019-08-30 | Акселерон Фарма Инк. | Способы и композиции для лечения миелофиброза |
| US11013785B2 (en) | 2016-11-10 | 2021-05-25 | Keros Therapeutics, Inc. | Activin receptor type IIA variants and methods of use thereof |
| DK3638243T3 (da) * | 2017-06-14 | 2024-10-28 | Celgene Corp | Fremgangsmåder til behandling af myeloproliferativ neoplasma-forbundet myelofibrose og anæmi |
| KR20200085832A (ko) | 2017-11-09 | 2020-07-15 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| CN120535607A (zh) | 2018-01-12 | 2025-08-26 | 科乐斯疗法公司 | 激活素受体iib型变体及其使用方法 |
| EP3788065B1 (en) | 2018-04-30 | 2025-08-27 | The Children's Hospital Of Philadelphia | Improving anemias by combining agents |
| AU2019266314B2 (en) | 2018-05-09 | 2025-05-15 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| KR20210088548A (ko) * | 2018-10-31 | 2021-07-14 | 셀진 코포레이션 | 액티빈-actrii 리간드 트랩을 사용하는 고리 철적혈모구가 있는 대상체에서 매우 낮은, 낮은 또는 중간 위험 골수이형성 증후군으로 인한 빈혈의 치료 |
| MX2022000782A (es) | 2019-07-19 | 2022-04-18 | Vifor Int Ag | Inhibidores de la ferroportina para el uso en el tratamiento de la beta-talasemia dependiente de transfusiones (tdt). |
| CN112924684B (zh) * | 2019-12-05 | 2022-07-29 | 中国科学院大连化学物理研究所 | 用于区分抑郁症和非抑郁症的生物标志物和包括其的诊断试剂盒 |
| EP4121088A4 (en) | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| BR112022020628A2 (pt) * | 2020-04-13 | 2022-11-29 | Celgene Corp | Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
| EP4240399A4 (en) * | 2020-11-06 | 2024-10-09 | Acceleron Pharma Inc. | FORMULATIONS WITH ACTRII POLYPEPTIDE VARIANTS |
| US20240181007A1 (en) * | 2021-01-08 | 2024-06-06 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| CA3205845A1 (en) | 2021-01-20 | 2022-07-28 | Francesca VINCHI | Ferroportin-inhibitors for the use in the treatment of myelodysplastic syndromes (mds) |
| WO2025003139A1 (en) | 2023-06-26 | 2025-01-02 | Vifor (International) Ag | Ferroportin-inhibitors for the use in the treatment of hereditary haemochromatosis (hh) |
| WO2025122830A1 (en) * | 2023-12-08 | 2025-06-12 | Keros Therapeutics, Inc. | Methods of using activin receptor type ii signaling inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4247A (en) * | 1845-11-01 | Jordan l | ||
| US6231880B1 (en) * | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
| EP2468290B1 (en) * | 2006-12-18 | 2015-04-01 | Acceleron Pharma, Inc. | Activin-ActRII Antagonists for use in treating anemia |
| US20100015144A1 (en) * | 2008-06-26 | 2010-01-21 | Acceleron Pharma Inc. | Methods for dosing an activin-actriia antagonist and monitoring of treated patients |
| US8058229B2 (en) * | 2008-08-14 | 2011-11-15 | Acceleron Pharma Inc. | Method of increasing red blood cell levels or treating anemia in a patient |
| MX340451B (es) * | 2009-09-09 | 2016-07-08 | Acceleron Pharma Inc | Antagonistas de actriib y dosificacion y usos de los mismos. |
| DK3520805T3 (da) * | 2011-10-17 | 2021-04-19 | Acceleron Pharma Inc | Sammensætninger til behandling af myelofibrose |
| EP2830642B1 (en) * | 2012-03-30 | 2019-08-28 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of iduronate- 2-sulfatase |
| WO2014066486A2 (en) * | 2012-10-24 | 2014-05-01 | Celgene Corporation | Biomarker for use in treating anemia |
| US20150266950A1 (en) * | 2012-10-24 | 2015-09-24 | Celgene Corporation | Methods for treating anemia |
| MX361412B (es) * | 2012-11-27 | 2018-12-05 | Childrens Medical Center | Direccion de elementos reguladores distales de bcl11a para reinduccion de hemoglobina fetal. |
-
2016
- 2016-05-12 TN TNP/2017/000468A patent/TN2017000468A1/en unknown
- 2016-05-12 WO PCT/US2016/031999 patent/WO2016183280A1/en not_active Ceased
- 2016-05-12 CA CA2985777A patent/CA2985777A1/en active Pending
- 2016-05-12 KR KR1020177035838A patent/KR102640198B1/ko active Active
- 2016-05-12 IL IL284686A patent/IL284686B2/en unknown
- 2016-05-12 US US15/573,177 patent/US20180125928A1/en not_active Abandoned
- 2016-05-12 CN CN201680041002.2A patent/CN107847562A/zh active Pending
- 2016-05-12 MY MYPI2017704290A patent/MY189601A/en unknown
- 2016-05-12 JP JP2017559025A patent/JP6976859B2/ja not_active Expired - Fee Related
- 2016-05-12 EP EP16793499.1A patent/EP3294320A4/en active Pending
- 2016-05-12 HK HK18110608.3A patent/HK1251157A1/zh unknown
- 2016-05-12 TW TW110148304A patent/TWI814187B/zh active
- 2016-05-12 AU AU2016261913A patent/AU2016261913B2/en active Active
- 2016-05-12 TW TW105114763A patent/TWI762444B/zh active
- 2016-05-12 JO JOP/2016/0092A patent/JOP20160092B1/ar active
-
2017
- 2017-11-08 IL IL255527A patent/IL255527B/en unknown
- 2017-11-16 PH PH12017502079A patent/PH12017502079A1/en unknown
-
2021
- 2021-08-13 JP JP2021131870A patent/JP2021191755A/ja active Pending
- 2021-10-29 AU AU2021258087A patent/AU2021258087B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520094A5 (cg-RX-API-DMAC7.html) | ||
| TWI658834B (zh) | 用於治療或預防ｃ５相關疾病的醫藥組合物以及治療或預防ｃ５相關疾病的方法 | |
| TWI754622B (zh) | Ctla4結合劑 | |
| JP2024009946A (ja) | 抗ｐｄ－１抗体と他の抗体の組み合わせを含む組成物 | |
| KR102560808B1 (ko) | 응고 제 ix 인자 및/또는 활성화 응고 제 ix 인자 및 응고 제 x 인자 및/또는 활성화 응고 제 x 인자를 인식하는 이중특이성 항체의 사용법 | |
| HRP20230504T1 (hr) | Antagonisti aktivin-actrii i upotreba u liječenju mijelodisplastičnog sindroma | |
| JP2016514132A5 (cg-RX-API-DMAC7.html) | ||
| JP6672533B1 (ja) | Ｃ５関連疾患の治療または予防用の医薬組成物およびｃ５関連疾患を治療または予防するための方法 | |
| AU2019374363A1 (en) | TGF-β receptor fusion protein pharmaceutical composition and use thereof | |
| JP2016527286A5 (cg-RX-API-DMAC7.html) | ||
| US10471142B2 (en) | Combination therapy using immunoglobulin and C1-Inhibitor | |
| RU2017111228A (ru) | Композиции антитела против IL-7R | |
| RU2015116264A (ru) | Композиции и способы лечения сердечной недостаточности у пациентов с диабетом | |
| JP2015532293A5 (ja) | 糖尿病患者における心不全の治療用組成物 | |
| JP2017524675A5 (cg-RX-API-DMAC7.html) | ||
| WO2020243603A1 (en) | Dosing of bispecific t cell engager | |
| TW202222823A (zh) | 投與治療劑量的雙特異性ｔ細胞接合分子治療癌症之方法 | |
| Ochi et al. | Bispecific antibodies for multiple myeloma: past, present and future | |
| JP2020505350A5 (cg-RX-API-DMAC7.html) | ||
| Hill et al. | Coversin, a novel C5 complement inhibitor, is safe and effective in the treatment of PNH: results of a phase II clinical trial | |
| TW201828984A (zh) | 使用介白素-17(il-17)拮抗劑治療痤瘡的方法 | |
| NZ737043A (en) | Treatment of beta-thalassemia using actrii ligand traps | |
| Lindfelt | Drugs That Act on the Immune System: Cytokines and Monoclonal Antibodies | |
| WO2023149443A1 (ja) | 臍帯血移植後の血球回復のための医薬組成物 | |
| CA2848510C (en) | Combination therapy using immunoglobulin and c1-inhibitor |